Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | LMNA | P02545 | 5/20 | 0.65 |
| ▸ | HTT | P42858 | 4/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.55 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.55 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116278 | 0.93 | MAPT (0.56) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4104678 | 0.92 | KMT2A (0.68) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4106286 | 0.91 | MAPT (0.65) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4117429 | 0.90 | MAPT (0.62) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4107026 | 0.87 | MAPT (0.57) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4118285 | 0.87 | CA2 (0.64) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4112724 | 0.87 | TP53 (0.70) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4118632 | 0.86 | MAPT (0.64) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4124728 | 0.86 | MAPT (0.57) | KMT2AMAPTSMN1; SMN2MEN1LMNA | |
| SCHEMBL4123178 | 0.86 | MAPT (0.60) | KMT2AMAPTSMN1; SMN2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | claimed |
| EP-1804785-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-07-11 | — | — | EP | claimed |
| WO-2006049941-A2 | DIARYL UREAS AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | WO | claimed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | KMT2A 2807/4885MAPT 1654/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.